Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 5/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13916085 | 0.76 | CYP1A2 (0.51) | CYP1A2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL10813052 | 0.76 | CYP1A2 (0.59) | CYP1A2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL744450 | 0.76 | ATIC (0.39) | KDM4EALDH1A1HSD17B10ATICHTT | |
| SCHEMBL9838795 | 0.74 | CYP1A2 (0.49) | CYP1A2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL10808383 | 0.73 | CYP1A2 (0.48) | CYP1A2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL10809113 | 0.73 | GART (0.48) | CYP1A2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL13833239 | 0.72 | KDM4E (0.49) | CYP1A2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6305981 | 0.71 | DHFR (0.48) | HTT | |
| Xanthopterin SCHEMBL6475881 | 0.66 | KDM4E (0.96) | KDM4EMEN1ALDH1A1MAPTTHRB | |
| SCHEMBL10984818 | 0.66 | HCAR2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | claimed |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | claimed |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2011-09-15 | — | — | US | claimed |
| EP-2341906-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | claimed |
| EP-2341911-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2010039997-A9 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-05 | — | — | WO | claimed |
| WO-2010051127-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-06 | — | — | WO | claimed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | claimed |
| EP-4709853-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024235844-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-21 | — | — | WO | disclosed |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| EP-3718560-A2 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | The University of North Carolina at Chapel Hill (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3406260-B1 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200054639-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-02-20 | — | — | US | disclosed |
| EP-2341906-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2341911-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010039997-A9 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010132725-A2 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010051127-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054639-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | MCL1, MPL, BCL9 | CYP1A2 3888/4885KDM4E 3100/4885MEN1 1013/4885 |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CYP1A2 4281/4885KDM4E 514/4885MEN1 3244/4885 |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK4, CDK6, CDKN1A | CYP1A2 4370/4885KDM4E 504/4885MEN1 2750/4885 |
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CYP1A2 4281/4885KDM4E 514/4885MEN1 3244/4885 |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | MCL1, MPL, BCL9 | CYP1A2 3888/4885KDM4E 3100/4885MEN1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.